Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flutamide

FDA-approved product (capsule, oral), marketed as Eulexin, Flutamide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

    NCT01546987 · start 2012-05

    Registered record
    Registry ID
    NCT01546987
    Conditions
    Prostate Cancer
    Interventions
    GnRH agonist; Anti-androgen; TAK-700; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2025-09-04
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionGnRH agonist; Anti-androgen; TAK-700; Radiation therapy
    PhasePhase 3
    Registry statusCompleted

  • Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

    NCT00936390 · start 2009-09

    Registered record
    Registry ID
    NCT00936390
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; LHRH agonist (antagonist) therapy; Dose-Escalated Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2025-09-04
    Enrolment
    1,538

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; LHRH agonist (antagonist) therapy; Dose-Escalated Radiation Therapy
    PhasePhase 3
    Registry statusCompleted

  • Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

    NCT00850941 · start 2009-01-26

    Registered record
    Registry ID
    NCT00850941
    Conditions
    Prostate Cancer
    Interventions
    Questionnaire
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-01-26
    Completion
    2021-01
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionQuestionnaire
    PhaseNot recorded
    Registry statusUnknown

  • Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

    NCT00930228 · start 2009-01

    Registered record
    Registry ID
    NCT00930228
    Conditions
    Polycystic Ovary Syndrome
    Interventions
    Flutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2009-01
    Completion
    2024-08
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome
    InterventionFlutamide; Placebo
    PhasePhase 1
    Registry statusUnknown

  • Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

    NCT00528866 · start 2008-04

    Registered record
    Registry ID
    NCT00528866
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; docetaxel; flutamide; LHRH agonist; 3-dimensional conformal radiation therapy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-04
    Completion
    2018-05-14
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; docetaxel; flutamide; LHRH agonist +2 more
    PhasePhase 2
    Registry statusCompleted

  • Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

    NCT00567580 · start 2008-02

    Registered record
    Registry ID
    NCT00567580
    Conditions
    Prostate Cancer
    Interventions
    PBRT; PLNRT; AA; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    1,792

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPBRT; PLNRT; AA; LHRH agonist
    PhasePhase 3
    Registry statusUnknown

  • Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

    NCT00512668 · start 2007-09

    Registered record
    Registry ID
    NCT00512668
    Conditions
    Adenocarcinoma of the Prostate; Recurrent Prostate Cancer
    Interventions
    leuprolide acetate; goserelin acetate; bicalutamide; nilutamide; flutamide; temsirolimus; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-09
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Recurrent Prostate Cancer
    Interventionleuprolide acetate; goserelin acetate; bicalutamide; nilutamide +3 more
    PhasePhase 1
    Registry statusTerminated

  • Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

    NCT00309985 · start 2006-09-26

    Registered record
    Registry ID
    NCT00309985
    Conditions
    Metastatic Hormone-sensitive Prostate Cancer
    Interventions
    androgen-deprivation therapy; docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-09-26
    Completion
    2025-01-31
    Enrolment
    790

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-sensitive Prostate Cancer
    Interventionandrogen-deprivation therapy; docetaxel
    PhasePhase 3
    Registry statusCompleted

  • Metabolic Syndrome in PCOS: Precursors and Interventions

    NCT00442689 · start 2006-07

    Registered record
    Registry ID
    NCT00442689
    Conditions
    Polycystic Ovary Syndrome; Metabolic Syndrome
    Interventions
    flutamide; ethinyl estradiol 35 mcg and drospirenone 3 mg; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-07
    Completion
    2012-11
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Metabolic Syndrome
    Interventionflutamide; ethinyl estradiol 35 mcg and drospirenone 3 mg; placebo
    PhaseNot applicable
    Registry statusCompleted

  • Prostate Adenocarcinoma TransCutaneous Hormones

    NCT00303784 · start 2006-03

    Registered record
    Registry ID
    NCT00303784
    Conditions
    Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer
    Interventions
    Goserelin; Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-03
    Completion
    2021-08
    Enrolment
    2,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnemia; Cardiovascular Complications; Hot Flashes; Osteoporosis +1 more
    InterventionGoserelin; Estradiol
    PhasePhase 3
    Registry statusUnknown

  • External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

    NCT00388804 · start 2005-02

    Registered record
    Registry ID
    NCT00388804
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Bicalutamide; Leuprolide; Goserelin; Flutamide; Questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-02
    Completion
    2011-04
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Bicalutamide; Leuprolide; Goserelin +2 more
    PhasePhase 3
    Registry statusTerminated

  • Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

    NCT00699907 · start 2005-01

    Registered record
    Registry ID
    NCT00699907
    Conditions
    Ovarian Cancer
    Interventions
    flutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-01
    Completion
    2014-11
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    Interventionflutamide
    PhasePhase 2
    Registry statusCompleted

  • Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

    NCT00170157 · start 2004-06

    Registered record
    Registry ID
    NCT00170157
    Conditions
    Prostate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    Bicalutamide; Flutamide; Goserelin Acetate; Ipilimumab; Leuprolide Acetate; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-06
    Completion
    2013-06
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer +1 more
    InterventionBicalutamide; Flutamide; Goserelin Acetate; Ipilimumab +2 more
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

    NCT01011751 · start 2004-04

    Registered record
    Registry ID
    NCT01011751
    Conditions
    Adenocarcinoma, Prostate
    Interventions
    Cyproterone acetate; Medroxyprogesterone acetate; Venlafaxine; Leuprorelin; Flutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2007-12
    Enrolment
    311

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma, Prostate
    InterventionCyproterone acetate; Medroxyprogesterone acetate; Venlafaxine; Leuprorelin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

    NCT00054106 · start 2002-12-10

    Registered record
    Registry ID
    NCT00054106
    Conditions
    Prostate Cancer
    Interventions
    buserelin; custirsen sodium; flutamide; conventional surgery; neoadjuvant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-12-10
    Completion
    2008-09-22
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbuserelin; custirsen sodium; flutamide; conventional surgery +1 more
    PhasePhase 1
    Registry statusCompleted